The Chemours Company Reports First Quarter 2026 Results: Detailed Analysis for Investors

Key Highlights and Potential Share Price Drivers

• Net Sales: Chemours posted Q1 2026 net sales of \$1.381 billion, up 1% year-over-year and 4% sequentially from Q4 2025.
• Net Loss: The company reported a net loss attributable to Chemours of \$29 million (\$0.19 per diluted share), a significant increase from the \$5 million loss (\$0.03 per diluted share) in Q1 2025.
• Adjusted Net Income & EBITDA: Adjusted net income was \$8 million (\$0.05 per diluted share), down from \$19 million (\$0.13 per share) in Q1 2025. Adjusted EBITDA rose slightly to \$169 million from \$166 million a year ago.
• Segment Performance:
  • Thermal & Specialized Solutions (TSS): Delivered record first quarter results, driven by double-digit sales growth in Opteon® Refrigerants. Net Sales increased 22%. This segment continues to be a bright spot for Chemours.
  • Titanium Technologies (TT): Net Sales were \$559 million, down 6% yoy due to a 7% volume decline. Adjusted EBITDA dropped sharply to \$18 million from \$50 million, with margin shrinking from 8% to 3%. Chemours announced a global TiO₂ price increase effective April 1, 2026, following December 2025 price actions, achieving a sequential price increase of 3%.
  • Advanced Performance Materials (APM): Net Sales fell 17% to \$243 million, primarily due to a 19% drop in volume, stemming from the Washington Works plant outage and the closure of SPS Capstone™ line. Adjusted EBITDA plummeted 84% to \$5 million, with margin dropping from 11% to 2%.
• Property Sale and Debt Reduction: Chemours received ~\$287 million net proceeds from selling most of its Kuan Yin site, positioning it to pay down €140 million in outstanding debt. This improves liquidity and reduces leverage.
• Liquidity: As of March 31, 2026, gross debt stood at \$4.2 billion, net debt at \$3.6 billion (after \$563 million in unrestricted cash), and net leverage ratio at 4.9x trailing twelve-month Adjusted EBITDA. Total liquidity was \$1.5 billion, including cash and revolving credit facility capacity.
• Free Cash Flows: Q1 2026 saw a negative free cash flow of \$93 million, an improvement from negative \$196 million in Q1 2025.
• Corporate Expenses: Corporate expenses were \$47 million, down by \$10 million yoy, mainly due to lower legacy litigation costs.
• Guidance:
  • Q2 2026 Outlook: Chemours expects consolidated net sales to increase 15-20% sequentially, driven by seasonal trends. Adjusted EBITDA is projected at \$220-\$250 million, corporate expenses around \$45-\$50 million, capital expenditures of ~\$50 million, and free cash flow of at least \$100 million. TSS net sales expected to grow in low-to-mid teens percentage, with Adjusted EBITDA \$210-\$220 million. TT Adjusted EBITDA expected at \$35-\$45 million, APM at \$12-\$18 million.
  • Full Year 2026 Outlook: Net sales expected to grow 3-5% over 2025, Adjusted EBITDA in the range of \$800-\$900 million. Capex estimated at \$275-\$325 million, free cash flow conversion above 20%. Net leverage ratio expected to fall below 3.8x by year-end.
• Non-GAAP Measures: Chemours continues to use Adjusted Net Income, Adjusted EPS, and Adjusted EBITDA to provide transparency in financial performance, especially as it excludes certain non-recurring and non-operational items (notably litigation, environmental charges, and asset sales/gains/losses).

Segment Deep Dive & Price Sensitivity

Thermal & Specialized Solutions (TSS)

This segment posted a robust performance, with record Q1 results and continued strong demand for Opteon® refrigerants. Double-digit sales growth and pricing power in North America are notable. Investors should note that TSS is the main earnings driver, and continued pricing momentum here is likely to positively impact share value.

Titanium Technologies (TT)

TT saw a 6% decline in net sales and a dramatic drop in EBITDA, largely due to lower volumes and an unfavorable ore mix. However, the sequential price increase (3%) and global price hike effective April 1, 2026, may improve future margins. Any stabilization or recovery in this segment could be a positive catalyst for the stock.

Advanced Performance Materials (APM)

APM suffered from production outages and a major product line closure, causing sharp sales and EBITDA declines. These operational issues are material and could weigh on investor sentiment unless resolved. However, the company expects recovery in Q2 as outages are resolved.

Property Sale and Debt Reduction

Chemours’ successful sale of its Kuan Yin site and debt paydown is a significant liquidity event. Lower leverage and improved cash position may positively impact share price, especially as the company targets a net leverage below 3.8x by year-end.

Litigation and Environmental Charges

The company continues to exclude litigation-related and environmental charges from its adjusted metrics. Lower legacy litigation costs in Q1 reduced corporate expenses. Investors should monitor any developments on legacy PFAS liabilities and environmental settlements, which can materially impact Chemours’ financials and share price.

Guidance and Forward-Looking Statements

Chemours provided strong Q2 and full-year guidance, expecting sequential revenue growth, margin improvement, and continued debt reduction. Investors should watch for actual delivery versus guidance, as misses or beats can move the stock notably.

Other Noteworthy Financial Metrics

• Gross profit: \$212 million vs. \$236 million in Q1 2025.
• SG&A Expense: Increased to \$147 million from \$123 million, reflecting higher operational costs.
• Interest expense: \$69 million, up slightly from \$66 million.
• Balance Sheet: Total liabilities stood at \$7.05 billion, with equity at \$216 million.
• Free Cash Flow Conversion: Expected at 21-27% for 2026, showing improved cash generation.

Risks and Uncertainties

Chemours’ forward-looking statements are subject to numerous risks, including environmental liabilities, regulatory changes, litigation, supply chain disruptions, macroeconomic and geopolitical factors, and operational outages. Investors should be aware that any adverse developments in these areas could significantly affect share value.

Conclusion

Chemours’ Q1 2026 report contains several price-sensitive items: strong TSS segment performance, a major property sale and debt reduction, sequential price increases in TT, and improved liquidity. However, operational challenges in APM and TT, and ongoing litigation/environmental risks remain concerns. The company’s guidance for Q2 and full-year 2026 appears optimistic, and delivery against these targets will be closely watched by investors. Any deviation from guidance or material litigation/environmental developments could move the share price significantly.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The information herein is based on Chemours Company’s Q1 2026 financial report and may be subject to change. Past performance is not indicative of future results.

View Chemours Co Historical chart here